Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Watchlist Manager
Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Watchlist
Price: 4.41 USD 2.08%
Market Cap: 199.7m USD

Intrinsic Value

YMAB's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one YMAB stock under the Base Case scenario is 9.99 USD. Compared to the current market price of 4.41 USD, Y-mAbs Therapeutics Inc is Undervalued by 56%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

YMAB Intrinsic Value
9.99 USD
Undervaluation 56%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Y-mAbs Therapeutics Inc

Valuation History Unavailable

Historical valuation for YMAB cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Y-mAbs Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Y-mAbs Therapeutics Inc

Current Assets 90.4m
Cash & Short-Term Investments 60.3m
Receivables 17.7m
Other Current Assets 12.4m
Non-Current Assets 22.2m
PP&E 762k
Intangibles 2.2m
Other Non-Current Assets 19.2m
Efficiency

Free Cash Flow Analysis
Y-mAbs Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Y-mAbs Therapeutics Inc

Revenue
88.7m USD
Cost of Revenue
-15.9m USD
Gross Profit
72.8m USD
Operating Expenses
-103.6m USD
Operating Income
-30.8m USD
Other Expenses
2.6m USD
Net Income
-28.2m USD
Fundamental Scores

YMAB Profitability Score
Profitability Due Diligence

Y-mAbs Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

31/100
Profitability
Score

Y-mAbs Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

YMAB Solvency Score
Solvency Due Diligence

Y-mAbs Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Y-mAbs Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

YMAB Price Targets Summary
Y-mAbs Therapeutics Inc

Wall Street analysts forecast YMAB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for YMAB is 16.13 USD with a low forecast of 3.03 USD and a high forecast of 27.3 USD.

Lowest
Price Target
3.03 USD
31% Downside
Average
Price Target
16.13 USD
266% Upside
Highest
Price Target
27.3 USD
519% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Y-mAbs Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for YMAB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

YMAB Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one YMAB stock?

The intrinsic value of one YMAB stock under the Base Case scenario is 9.99 USD.

Is YMAB stock undervalued or overvalued?

Compared to the current market price of 4.41 USD, Y-mAbs Therapeutics Inc is Undervalued by 56%.

Back to Top